Literature DB >> 11311223

Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers.

P Peichl1, A Griesmacherb, R Marteau, S Hejc, W Kumpan, M M Müller, H Bröll.   

Abstract

In this study we evaluated the routine practice and clinical application of serum crosslaps to urinary-crosslaps, -N-telopeptide-related fraction of type 1 collagen, -deoxpyridinoline, -totalpyridinoline and serum osteocalcin. The utility of both the serum and urine immunoassays for bone formation and resorption marker were tested in a cohort of 593 female and male patients from our outpatient clinic for osteology and rheumatology and compared to important osteoporosis risk factors like age, gender, E2 deficiency, bone density and chronic renal failure. The biochemical maker of bone formation, serum osteocalcin exhibit significant correlations to all five tested serum and urinary markers of bone resorption (p < 0.0001) crosswise to all different groups of patients. The group of chronic renal failure patients showed no significant correlation between the tested bone turnover parameters and the serum creatinine level except a significant increase and correlation for serum crosslaps and for the ratio of serum and urinary crosslaps. Associations between the age of the patients and the markers of bone turnover were rather poor. We found a significant, negative association between serum and urinary bone turnover markers and bone density and were interested, whether in patients with bone density < 2.5 SD an enhanced bone turnover could be detected in the same way as for E2 deficiency. Applying a discriminant analysis it was possible to discriminate between the patient with BD < 2.5 SD and those with BD > 1.0 SD with a sensitivity of 70% and a specificity of 65% using serum crosslaps. In case of urinary crosslaps the discriminatory power was slightly lower (sensitivity: 65.6%, specificity: 67.5%) and for serum osteocalcin the discriminatory power was negligible higher (sensitivity: 79%, specificity: 56%). The highly significant correlation between the urinary and serum crosslinked peptides by ELISA and serum osteocalcin supports the concept that these respective indices of bone formation and resorption both in urine and serum reflect a coupled process in vivo with sensitivity and specificity to pathological bone density, estrogen deficiency and chronic renal failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311223     DOI: 10.1016/s0009-9120(01)00193-x

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  6 in total

1.  Association of bone turnover markers with mortality in men referred to coronary angiography.

Authors:  E Lerchbaum; V Schwetz; S Pilz; T B Grammer; M Look; B O Boehm; B Obermayer-Pietsch; W März
Journal:  Osteoporos Int       Date:  2012-07-10       Impact factor: 4.507

2.  Estimation of serum osteocalcin and telopeptide-C in postmenopausal osteoporotic females.

Authors:  M Lateef; M Baig; A Azhar
Journal:  Osteoporos Int       Date:  2009-07-14       Impact factor: 4.507

3.  A label-free electronic biosensor for detection of bone turnover markers.

Authors:  Yeo-Heung Yun; Amit Bhattacharya; Nelson B Watts; Mark J Schulz
Journal:  Sensors (Basel)       Date:  2009-10-12       Impact factor: 3.576

4.  Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial.

Authors:  Verena Schwetz; Christian Trummer; Marlene Pandis; Martin R Grübler; Nicolas Verheyen; Martin Gaksch; Armin Zittermann; Winfried März; Felix Aberer; Angelika Lang; Gerlies Treiber; Claudia Friedl; Barbara Obermayer-Pietsch; Thomas R Pieber; Andreas Tomaschitz; Stefan Pilz
Journal:  Nutrients       Date:  2017-04-27       Impact factor: 5.717

5.  Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional links.

Authors:  A Fisher; W Srikusalanukul; M Davis; P Smith
Journal:  Clin Interv Aging       Date:  2013-02-25       Impact factor: 4.458

6.  Parathyroid hormone and bone marker levels in patients with morbid obesity before and after biliopancreatic diversion.

Authors:  J Moreiro; O Ruiz; G Perez; R Salinas; J R Urgeles; M Riesco; M García-Sanz
Journal:  Obes Surg       Date:  2007-03       Impact factor: 3.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.